Cardiovascular biomarkers in dogs with systemic inflammatory response syndrome

Kris Gommeren DVM, DECVIM, DECVECC1 | Isabelle Desmas DVM, DACVIM1
Alexandra Garcia DVM1 | Cécile Clercx DVM, DECVIM, PhD1 | Kathleen McEntee DVM, DECVIM, PhD2 | Anne-Christine Merveille DVM, PhD1 | Dominique Peeters DVM, DECVIM, PhD1

1Department of Clinical Sciences, School of Veterinary Medicine, University of Liège, Liège, Belgium
2Faculty of Medicine, Laboratory of Physiology, Université Libre de Bruxelles, Brussels, Belgium

Correspondence
Kris Gommeren, Boulevard de Colonster 20, 4000 Liège, Belgium.
Email: krisjeg@hotmail.com

Presented in part at the 21st ECVIM-CA Congress, Seville, Spain, September 2011.

Abstract
Objective: To measure plasma N-terminal fragments of pro-B-type natriuretic peptides (NT-proBNP) and cardiac troponin T (cTnT) concentration in hospitalized dogs and relate these markers to underlying conditions and evaluate their potential as prognostic markers in dogs with systemic inflammatory response syndrome (SIRS).

Design: Prospective, observational, clinical study.

Setting: Emergency department of a university teaching hospital.

Animals: Sixty-nine dogs with SIRS examined in the emergency department were prospectively studied. Patient age ranged from 5 months to 15 years, and weight ranged from 5.5 to 75 kg.

Measurements and Main Results: Blood samples were obtained at presentation, during hospitalization until discharge or death, and at a “control” visit (T1m) at least 1 month after hospital discharge. NT-proBNP was assayed with a commercially available canine ELISA, while cTnT was measured with an automated immunoassay previously used in dogs. A correlation procedure, mixed procedure on a linear model, and a logistic procedure were performed. Forty-four patients survived, 19 of which had control visits. cTnT concentrations were significantly higher than T0 and T1m at T12, T24, and T72. In 28 dogs, cTnT was detected during hospitalization, but cTnT was not detected in any dog at the control visits. Higher concentrations of cTnT were negatively associated with survival, irrespective of disease category. NT-proBNP concentrations were significantly higher than T0, T6, T12, and T1m at T24, T72, and T120, but were not associated with survival.

Conclusions: NT-proBNP and cTnT increased significantly in dogs with SIRS, regardless of the underlying disease process. Nonsurvivors displayed significantly higher cTnT concentrations during hospitalization.

KEYWORDS
brain natriuretic peptide, cardiac troponin, prognosis, SIRS

1INTRODUCTION

The systemic inflammatory response syndrome (SIRS) characterizes the systemic repercussions of inflammation. The list of underlying causes of SIRS is diverse, including sepsis, trauma, and sterile inflammatory conditions such as pancreatitis.1 The criteria for SIRS are based on defined changes in clinical (body temperature, heart rate, and respiratory rate) and hematologic (leukocyte counts, presence
of a left shift) variables (Table 1). The diagnosis of SIRS recognizes the presence of clinical signs compatible with systemic inflammation, but the criteria are overly sensitive and poorly specific. Cardiac dysfunction secondary to systemic inflammation has been reported in human medicine, and is also known as myocardial hibernation. Myocardial hibernation has been reported in critically ill human patients and studied in dogs with experimentally induced sepsis. It is characterized by increased end-diastolic and end-systolic ventricular volumes, and systolic and diastolic ventricular dysfunction. Whether myocardial hibernation serves as a protective mechanism of the body during systemic inflammation, or whether it has a negative impact on survival is unknown. Myocardial hibernation has been associated with increased blood concentrations of cardiac troponins (cTn) and natriuretic peptides in people with SIRS, and some studies have found concentrations of cTn and the N-terminal portion of pro-brain natriuretic peptide (NT-proBNP) to be correlated with the degree of cardiac dysfunction and with plasma concentrations of inflammatory cytokines. Very little is known about myocardial hibernation in dogs with naturally occurring disease, although it is likely to occur. Recent data suggest that plasma concentrations of cardiac biomarkers are increased in dogs with SIRS. As these cardiac biomarkers may help in the diagnosis of cardiac dysfunction and the evaluation of prognosis in people with SIRS, they may also be useful to evaluate dogs with SIRS.

Cardiac troponins T and I (cTnT and cTnI, respectively) are sensitive and specific for the detection of myocardial ischemic necrosis or reversible myocardial injury, and increased plasma cTnT and cTnI concentrations are associated with a poorer prognosis in critically ill people. Cardiac troponins have been studied in veterinary patients with cardiac disease, and are also increased and associated with poor prognosis in other syndromes such as gastric dilation and volvulus, trauma, and infections. Brain natriuretic peptide (BNP) and NT-proBNP are quantitative markers of ventricular wall stress with high sensitivity and specificity for cardiac insult. Several studies have associated increases in plasma BNP and NT-proBNP in people with sepsis and SIRS with myocardial hibernation and poor prognosis. In veterinary medicine, increased plasma NT-proBNP concentrations have been demonstrated in dogs with babesiosis and in dogs with traumatic, neurological, and gastrointestinal diseases. We hypothesized that plasma cTnT and NT-proBNP would increase during hospitalization, vary in magnitude according to the underlying etiology, and serve as a prognostic marker in canine patients with SIRS.

### TABLE 1 Clinical criteria for the diagnosis of SIRS (modified from Hauptman et al., with alterations in white blood cell count to adhere with the reference ranges of the clinical laboratory and temperature ranges as applied in clinics)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Limit</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart frequency</td>
<td>&gt;120</td>
<td>bpm</td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>&lt;20</td>
<td>rpm</td>
</tr>
<tr>
<td>Temperature</td>
<td>&lt;38 or &gt;39</td>
<td>°C</td>
</tr>
<tr>
<td>Leukocytosis/leukopenia</td>
<td>&gt;16,000 or &lt;5,000</td>
<td>/μL</td>
</tr>
<tr>
<td>Left shift on blood smear</td>
<td>&gt;3</td>
<td>%</td>
</tr>
</tbody>
</table>

2 | MATERIALS AND METHODS

All dogs that were examined in the emergency service of the University of Liège between January and August 2010 were considered for inclusion. Dogs were enrolled if SIRS was diagnosed based on the suspicion of an underlying disease process known to trigger the systemic inflammatory response and the finding of 2 or more abnormalities of the following clinical (temperature, heart rate, and respiratory rate) and basic laboratory parameters (leukocyte counts). The cutoff values for white blood cell counts were modified from the original paper to adhere with the reference ranges of our own clinical laboratory (Table 1) and the limits of normal rectal temperature were between 38 and 39°C. Approval for this project was obtained from the ethics committee (approval number 1709), and informed consent was obtained from the owners of each dog. Exclusion criteria included a weight <5 kg and animals that were considered too unstable to sustain any additional or unnecessary stress. Patients were grouped into 7 different disease categories: patients with neoplastic disease (N), infectious disease (I), GIV, gastrointestinal disease (GI), trauma (T), renal disease (R), and miscellaneous causes (M). Since concentrations of plasma NT-proBNP can be influenced by renal function, patients with renal insufficiency (defined as azotemia or oligo-anuria that was unresponsive to fluid therapy) were excluded from NT-proBNP analysis. Although plasma cTn concentrations also can be influenced by renal function, the severity of renal failure does not correlate with cTn concentrations, and cTn analysis remains useful in identifying myocardial injury in people with renal disease. Similarly, plasma cTn concentrations can identify human patients with poorer prognosis despite concurrent renal failure or requirement for hemodialysis. Based on these findings, we did not exclude patients with renal impairment from plasma cTnT analysis.

Baseline plasma concentrations of cTnT and NT-proBNP were assessed on blood sampled prior to starting any treatment (T0), and on samples obtained after 6 (T6), 12 (T12), 24 hours (T24), and every other day thereafter (T72, T120, etc.) until hospital discharge or death. Short-term survival was defined as patient discharge from the hospital, while long-term survival was defined as the patient being alive 1 month after discharge from the hospital. All long-term survivors were invited to a recheck "control" examination occurring between 1 month and 1 year after hospital discharge, where blood was again collected for analysis. All blood samples were divided into EDTA (4 mL) and serum (2 mL) tubes that were centrifuged and separated within 15 minutes, with the serum or plasma stored at −80°C until analysis.

A commercial electrochemiluminescence kit, with a lower limit of detection of 0.010 ng/mL, a limit of linearity of 25.00 ng/mL, and a coefficient of variation less than 5% for values above 0.06 ng/mL, was used to measure serum cTnT. The kit detected 2 epitopes of the central part of human cTnT (125-131 and 135-147), which are highly conserved in canine cTnT (one substitution in the first epitope and
A commercially available sandwich enzyme immune assay† with an upper limit of detection of 3,000 pmol/L was used to measure NT-proBNP. Patient plasma and an immunoaffinity purified sheep detection antibody conjugated to horseradish peroxidase were incubated for 5 hours at 20°C in microtiter plates with capture antibody (anti-NT-proBNP) bound to the wells. The wells were then washed and tetramethylbenzidine was added and incubated for 40 minutes, after which a stop solution was added and bound NT-proBNP was quantified by an ELISA plate reader. All plates were run with calibration and control solutions, yet for financial reasons only the first plate was run in duplicate.

2.1 | Statistical methods

Statistical analysis was performed using a commercially available statistics program.† A Shapiro–Wilk and Kolmogorov–Smirnov test (univariate procedure) and normality QQplots were performed on the raw data and on logarithmic-transformed data. For both cTnT and NT-proBNP, the logarithmically transformed data were used for analysis after identification of a nearly normal distribution of the residues on the QQplots. A mixed procedure on a generalized linear model was used to assess the relationship of measured clinical parameters to cardiac biomarkers. As the data were taken repeatedly over time on the same animals, there is a possible correlation between successive data. This correlation structure is reflected in the linear mixed model used (MIXED procedure, repeated by time). Correlation between different biomarkers was tested (CORR procedure). A logistic analysis (LOGISTIC procedure) was performed in order to evaluate the association of plasma cardiac biomarker concentrations with survival to discharge. Only dogs that survived, died of natural causes, or were euthanized for prognostic reasons were included in the assessment of prognostic value of the evaluated parameters. Statistical significance was set at a $P$-value < 0.05.

3 | RESULTS

Fifty-eight purebred and 11 mixed-breed dogs were included in the study. The most commonly represented breeds were Bernese Mountain Dog ($n = 8$), German Shepherd Dog ($n = 6$), Great Dane ($n = 4$), Jack Russell Terrier ($n = 4$), and Belgian Shepherd Dog ($n = 3$). There were 38 male (29 intact and 9 neutered) and 31 female (17 intact and 14 neutered) dogs with a median age of 6.5 years (ranging between 7 months and 15.2 years) and with a median weight of 30.3 kg (ranging from 5.5 to 75 kg). Patients were categorized by disease ($N = 13$; $I = 12$; GDV = 11; GI = 5; $T = 6$; $R = 3$; and $M = 19$). Outcome and follow-up of our studied population has been represented in a flow diagram (Figure 1). Forty-four patients were discharged, 8 died during hospitalization, and 17 dogs were euthanized (8 for prognostic, 7 for financial, and 2 for unspecified reasons). Thirty-four patients were still alive more than 1 month after discharge and 19 were presented for a control visit. Of the dogs that did not have a follow-up visit, 5 died from related causes before the scheduled visit (including continued gastrointestinal illness in 2 dogs, aspiration pneumonia secondary to a megaesophagus, worsening hepatocutaneous syndrome, and tumor recurrence with secondary hemoabdomen in 1 dog each), 5 owners declined, and 5 dogs were lost to follow-up.

3.1 | Biomarker analysis

Plasma concentrations of cTnT and NT-proBNP both changed significantly over time ($P < 0.0001$). Concentrations of cTnT and NT-proBNP at each timepoint are displayed in Figures 2 and 3, respectively. Twenty-eight of 69 dogs had at least 1 time point during hospitalization at which cTnT was detectable, while none of the dogs had measurable cTnT concentrations at the control visit. Plasma cTnT concentration was significantly higher at T12, T24, and T72 compared to concentrations at presentation and at the control visit (Table 2). Plasma NT-proBNP concentration was measurable in all dogs at all timepoints. Plasma NT-proBNP concentrations were significantly higher at T24, T72, and T120 compared to T0, T6, T12, and T1m. Median concentrations did not differ significantly between T24...
FIGURE 3  Plasma concentrations of NT-proBNP at different time points in dogs with SIRS. The central line of the box plot indicates the median value, the upper and lower line of the box plot illustrate the range of the 25% and 75% of the values, and the outer lines at the end of the vertical lines indicate the 95% and 5% range of the recorded values (661.39 [60.77–3,000] pmol/L), T72 (888.81 [76.58–3,000] pmol/L), and T120 (737.14 [0–3,000] pmol/L; Table 3).

3.2 Correlation of biomarkers with underlying disease, prognosis, and each other

Statistical analysis did not identify any influence of the underlying disease category on cTnT and NT-proBNP concentrations (P = 0.1618 and 0.084, respectively). Regardless of the specific timepoint, detectable cTnT concentrations (P = 0.0106) were associated with poor prognosis (Figure 4). In contrast, NT-proBNP concentrations were not correlated with survival to discharge (P = 0.5091, Figure 5). Finally, concentrations of cTnT and NT-proBNP were significantly and mildly correlated (P < 0.001, with R = 0.2913).

4 DISCUSSION

This study demonstrated changes in cardiac biomarkers during hospitalization in a population of canine patients with SIRS. Troponin

TABLE 2  P-values for cTnT concentrations between different time points in all canine SIRS patients

<table>
<thead>
<tr>
<th></th>
<th>T0</th>
<th>T6</th>
<th>T12</th>
<th>T24</th>
<th>T72</th>
<th>T120</th>
<th>T1m</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>1</td>
<td>0.0501</td>
<td>0.0002-</td>
<td>0.0004-</td>
<td>0.0231-</td>
<td>0.8514</td>
<td>0.0866</td>
</tr>
<tr>
<td>T6</td>
<td>0.0501</td>
<td>1</td>
<td>0.0677</td>
<td>0.0748</td>
<td>0.4441</td>
<td>0.368</td>
<td>0.0022-</td>
</tr>
<tr>
<td>T12</td>
<td>0.0002-</td>
<td>0.0677</td>
<td>1</td>
<td>0.9257</td>
<td>0.514</td>
<td>0.0572</td>
<td>&lt;0.0001-</td>
</tr>
<tr>
<td>T24</td>
<td>0.0004-</td>
<td>0.0748</td>
<td>0.9257</td>
<td>1</td>
<td>0.4769</td>
<td>0.0536</td>
<td>&lt;0.0001-</td>
</tr>
<tr>
<td>T72</td>
<td>0.0231-</td>
<td>0.4441</td>
<td>0.514</td>
<td>0.4769</td>
<td>1</td>
<td>0.174</td>
<td>0.001-</td>
</tr>
<tr>
<td>T120</td>
<td>0.8514</td>
<td>0.368</td>
<td>0.0572</td>
<td>0.0536</td>
<td>0.174</td>
<td>0.1634</td>
<td>1</td>
</tr>
<tr>
<td>T1m</td>
<td>0.0866</td>
<td>0.0022-</td>
<td>&lt;0.0001-</td>
<td>&lt;0.0001-</td>
<td>0.001-</td>
<td>0.1634</td>
<td>1</td>
</tr>
</tbody>
</table>

Significant differences are indicated in bold with an asterisk (*).

TABLE 3  P-values for NT-proBNP concentrations between different time points in all canine SIRS patients

<table>
<thead>
<tr>
<th></th>
<th>T0</th>
<th>T6</th>
<th>T12</th>
<th>T24</th>
<th>T72</th>
<th>T120</th>
<th>T1m</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>1</td>
<td>0.2712</td>
<td>0.2125</td>
<td>0.0008-</td>
<td>0.0004-</td>
<td>0.005-</td>
<td>0.9357</td>
</tr>
<tr>
<td>T6</td>
<td>0.2712</td>
<td>1</td>
<td>0.8849</td>
<td>0.0003-</td>
<td>&lt;0.0001-</td>
<td>0.0007-</td>
<td>0.4015</td>
</tr>
<tr>
<td>T12</td>
<td>0.2125</td>
<td>0.8849</td>
<td>1</td>
<td>0.0002-</td>
<td>&lt;0.0001-</td>
<td>0.0005-</td>
<td>0.3475</td>
</tr>
<tr>
<td>T24</td>
<td>0.0008-</td>
<td>0.0003-</td>
<td>0.0002-</td>
<td>1</td>
<td>0.2061</td>
<td>0.2321</td>
<td>0.0626</td>
</tr>
<tr>
<td>T72</td>
<td>0.0004-</td>
<td>&lt;0.0001-</td>
<td>&lt;0.0001-</td>
<td>0.2061</td>
<td>1</td>
<td>0.7928</td>
<td>0.0063-</td>
</tr>
<tr>
<td>T120</td>
<td>0.005-</td>
<td>0.0007-</td>
<td>0.0005-</td>
<td>0.2321</td>
<td>0.7928</td>
<td>1</td>
<td>0.0155-</td>
</tr>
<tr>
<td>T1m</td>
<td>0.9357</td>
<td>0.4015</td>
<td>0.3475</td>
<td>0.0626</td>
<td>0.0063-</td>
<td>0.0155-</td>
<td>1</td>
</tr>
</tbody>
</table>

Significant differences are indicated in bold with an asterisk (*).
The use of a cTnI assay in the present study (as admission to the ICU likely takes place later than admission to an intensive care unit) was not found to be higher than for cTnT, cTnI and cTnT carried similar prognostic value, identifying differences in concentration between survivors and nonsurvivors. Reports that evaluate plasma concentrations of cTnI and cTnT in dogs with SIRS have confirmed their prognostic value, identifying differences in concentration between survivors and nonsurvivors. Increased concentrations of NT-proBNP when screening for occult cardiac disease should therefore be interpreted carefully in patients that also have SIRS. Whether increased cTnT and NT-proBNP concentrations are indicative of myocardial hibernation in dogs with SIRS cannot be concluded from this paper but merits further investigation.

Detectable cTnT concentrations during hospitalization were associated with poor short-term prognosis. Cardiac troponin T and I are well-accepted prognostic biomarkers in human intensive care units. In veterinary medicine, increased concentrations of cTns have been observed in infectious disease patients, trauma patients, GDV patients, and patients suffering from systemic diseases and are correlated with poor prognosis in some of these reports. Reports that evaluate plasma concentrations of cTnI and cTnT in dogs with SIRS have confirmed their prognostic value, identifying differences in concentration between survivors and nonsurvivors. In one report, additional sampling to measure cTnI concentrations on day 2 or 3 (or evaluation of concentration changes) did not add value to the prognostic information.

Although the incidence of increased cTnT concentrations has been reported to be higher than for cTnT, cTnI and cTnT carried similar prognostic information. cTnT concentrations have been established as interesting markers to predict prognosis of canine SIRS patients, but cutoff limits remain to be determined. As cTnT (and cTnI) can remain increased up to 7 or 10 days after an insult, the kinetics of cTnT are difficult to evaluate, and they may be less useful for evaluation of disease progression.

In the present study, NT-proBNP concentrations were not significantly correlated with prognosis. Previous studies in dogs tended to evaluate natriuretic peptides at presentation, while higher concentrations should be expected later during hospitalization. This delay in the rise of NT-proBNP limits its use as a prognostic marker in a clinical veterinary emergency care setting. At later timepoints, the group size in this study rapidly decreased, which may have impacted the likelihood to identify significant differences between survivors and nonsurvivors. A recently published meta-analysis in human patients with sepsis concluded that NT-proBNP concentrations are significantly associated with risk of mortality.
concluded that increased NT-proBNP concentrations in the presence of SIRS or sepsis do not indicate cardiac dysfunction, but normal NT-proBNP concentrations rule out the need for further cardiac investigation.\textsuperscript{22} The lack of a significant difference in NT-proBNP concentration between survivors and nonsurvivors in this study should be confirmed in a larger cohort of patients with SIRS. The observed increased NT-proBNP concentrations in this study may be explained by myocardial hibernation, but also may have been increased due to increased cardiac wall stress after volume resuscitation,\textsuperscript{65} the presence of lung injury, acute respiratory distress syndrome, or thromboembolism.\textsuperscript{6}\n
There are several limitations to the present study. Dogs that were considered too unstable by the attending clinician were removed from the study, and therefore, more severely ill patients were less likely to enter the study. Consequently, findings might have been different if all dogs were included, regardless of their clinical status. Because sampling times were standardized with respect to the timing of presentation to the emergency department, disease may have been present for variable amounts of time prior to enrollment, and this may have altered the kinetics of the studied biomarkers. In addition, a large proportion of our patients were euthanized at the owner’s request, rather than based on specific study endpoints, which may have impacted our analysis of prognosis. In order to avoid any effect of financial considerations on the prognostic evaluation, all dogs that were euthanized for financial or unspecified reasons were removed from the prognosis analysis. In the present study, 44 patients survived to discharge (64%), which is similar to,\textsuperscript{66} or better than\textsuperscript{67} previous studies on clinical canine SIRS patients.

Samples with NT-proBNP concentrations above the upper limit of the assay (3,000 pmol/L) were not diluted to measure the exact concentration because of financial restrictions. Therefore, NT-proBNP concentration was underestimated in some samples. This did not prohibit the finding of significant changes, but may have underestimated the degree of those changes in NT-proBNP concentration. Similarly, a cTnT assay rather than a cTnI assay was used due to financial restrictions. The use of a cTnI assay may have resulted in a higher detection rate of increased troponin concentrations.

Our study demonstrates that cardiac biomarkers are often increased in dogs with SIRS presenting to the emergency department. Additionally, this study confirms that the cTnT concentration was associated with survival in dogs with SIRS. Studies investigating the correlation of cardiac biomarkers with echocardiographic findings and inflammatory cytokines in canine patients with SIRS are warranted.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ENDNOTES**

\footnote{1} Modular Analytics E, Roche, Basel, Switzerland\n
\footnote{2} VetSign Canine Cardioscreen Test Kit, IDEXX Laboratories, Westbrook, ME\n
\footnote{3} SAS; Statistical Analysis Software, Cary, NC

**REFERENCES**


58. Prosek R, Sisson DD, Oyama MA, et al. Distinguishing cardiac and noncardiac dyspnea in 48 dogs using plasma atrial natriuretic factor,


---